Brachial Plexus Injury Market Research Report- Forecast till 2027

Brachial Plexus Injury Market Information: By Type (Avulsion, Rupture, Neurapraxia, Others), By Diagnosis (Clinical Examination, Electrodiagnostic, others), By Treatment (Therapy, Surgery), By Drugs (Nsaids, Anticonvulsants, others), By Indication (Trauma, Inflammation, others) - Forecast till 2027

ID: MRFR/Pharma/2978-HCR | February 2021 | Region: Global | 206 pages

Brachial Plexus Injury Market Scenario


The brachial plexus is a network of nerves formed by intercommunication between the ventral roots of the lower four cervical nerves and the first thoracic nerves. Plexus are responsible to pass nerve signals to all the muscles of upper extremity. Brachial plexus injury occurs when the nerves are stretched or compressed. In severe cases, the nerves may be torn away from the spinal cord. Minor brachial plexus injury may result due to sport injuries such as football. The injuries can be treated by surgical procedure that would help to restore the functions of the nerves.


Increase in number of road accidents and sport injuries, availability of treatment options and growing demand for sports medicine are major drivers for the growth of this market. Furthermore, increase in the participation of adults in high energy sports also boost the market growth. Presence of large number of market players may restrict the entry of new players. The global brachial plexus injury market is expected to grow at a CAGR of 12.5% during the forecast period.


  FIGURE 1 Global Brachial Plexus Injury Market by Region, 2016 (%) Brachial Plexus Injury Market


Source: World Health Organization, Centers for Disease Control and Prevention, U.S. National Library of Medicine, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation

Key Players in the Global Brachial plexus injury Market  
     
Some of the key players in this market are Pfizer (U.S.), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), GlaxoSmithKline (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lily and Company (U.S.), AstraZeneca (U.S.) and Amgen (U.S.).  


Brachial Plexus Injury Market Segments
The global brachial plexus injury market is segmented on the basis of types which includes avulsion, rupture, neurapraxia, axonotemesis, neurotemesis and neuroma.
On the basis of diagnosis, the market is segmented into clinical examination, electro diagnostic studies and imaging studies. Electro diagnostic studies is segmented is sub-segmented into electromyography, Nerve Conduction Velocity (NCV), SNAP technology, and Somatosensory Evoked Potential (SSEP). Imaging studies is sub-segmented into CT, and MRI.
On the basis of treatment, the market is segmented into therapy and surgery. Therapy is segmented is sub-segmented into physical rehabilitation therapy, aquatic therapy, therapeutic taping, and aquatic therapy. Surgery is sub-segmented into nerve graft, nerve transfer and muscle transfer.


On the basis of drug, the market is segmented into Nonsteroidal anti-inflammatory drugs, Anticonvulsants, Tricyclic antidepressants and Analgesics.  Nonsteroidal anti-inflammatory drugs is segmented is sub-segmented into celecoxib and naproxen. Anticonvulsants is segmented is sub-segmented into gabapentin. Tricyclic antidepressants is segmented is sub-segmented into nortriptyline and doxepin. Analgesics is segmented is sub-segmented into methadone, oxycodone and others.


On the basis of indication, the market is segmented into trauma, inflammation, contact sports, tumors, radiation treatment and others.


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Brachial Plexus Injury Market Regional Analysis 
The American region accounts for the largest share of the global brachial plexus injury market due to flourishing growth of sports medicine and high rate of sport injures, which are important factors to boost the market.  According the Center of Disease Control and Prevention, 8.6 million sports injuries were reported annually in the U.S. Furthermore, rising survival rates of high speed motor vehicle collisions may increase the market for diagnosis and treatment of brachial plexus market. According to the Center of Disease Control and Prevention, more than 18,000 survive road accidents each year and received emergency treatment involving surgical procedures.

Europe is the second largest market that holds a noticeable share of the global brachial plexus injury market owing the availability of drugs for the treatment and an increase in the number of patients treated in emergency departments.


Asia Pacific is expected to be the fastest growing brachial plexus injury market owing to the high and ever increasing rates of traffic accidents in many of the Asia Pacific countries and the consequent demand for NSAIDs and other drugs. India is expected to be the largest market for Asia Pacific. According to the data from the Government of India reports, the total number of road accidents increased by 2.5 per cent from 4,89,400 in 2014 to 5,01,423 in 2015.


In the Middle East & Africa, the market shows steady but positive growth due to the continuous growth of healthcare diagnostics.


FIGURE 2 Research Methodology Global Brachial Plexus Injury Market


 



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 12.5%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Diagnosis, Treatment, Drugs and Indication
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer (U.S.), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), GlaxoSmithKline (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lily and Company (U.S.), AstraZeneca (U.S.) and Amgen (U.S.)
  Key Market Opportunities

  • The American region accounts for the largest share of the global market due to flourishing growth of sports medicine and high rate of sport injures
  • In Europe Region, global brachial plexus injury market owing the availability of drugs for the treatment and an increase in the number of patients treated in emergency departments.
  • Asia Pacific Region, High and ever increasing rates of traffic accidents in many of the Asia Pacific countries and the consequent demand for NSAIDs and other drugs.
  •   Key Market Drivers

  • Increase in number of road accidents and sport injuries
  • Availability of treatment options
  • Growing demand for sports medicine


  • Speak to Analyst Ask for Customization

    Table of Contents
    1 Report Prologue

    2 Introduction

    2.1 Definition

    2.2 Scope of Study

    2.3 Research Objective

    2.4 Market Structure

    3 Research Process

    3.1 Primary Research

    3.2 Secondary Research

    3.3 Market Size Estimation

    4 Market Dynamics

    4.1 Introduction

    4.2 Drivers

    4.3 Restraints

    4.4 Opportunities

    4.5 Macroeconomic Indicators

    5. Market Factor Analysis

    5.1 Porters five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain

    5.3 Investment Feasibility Analysis

    5.4 Price Factor Analysis

    6 Global Brachial Plexus Injury Market, by Type

    6.1 Introduction

    6.2 Avulsion

    6.3 Rupture

    6.4 Neurapraxia

    6.5 Axonotemesis

    6.6 Neurotemesis

    6.7 Neuroma

    7 Global Brachial Plexus Injury Market, By Drug

    7.1 Nonsteroidal anti-inflammatory drugs

    7.1.1 Celecoxib

    7.1.2 Naproxen

    7.2 Anticonvulsants

    7.2.1 Gabapentin

    7.3 Tricyclic antidepressants

    7.3.1 Nortriptyline

    7.3.2 Doxepin

    7.4 Analgesics

    7.4.1 Methadone

    7.4.2 Oxycodone

    7.4.3 Others

    8 Global Brachial Plexus Injury Market, By Diagnosis

    8.1 Introduction

    8.2 Clinical Examination

    8.3 Electrodiagnostic Studies

    8.3.1 Electromyography

    8.3.2 Nerve conduction velocity

    8.3.3 SNAP technology

    8.3.4 Somatosensory Evoked Potential

    8.4 Imaging Studies

    8.4.1 CT

    8.4.2 MRI

    9 Global Brachial plexus injury Market, by Treatment

    9.1 Introduction

    9.2 Therapy

    9.2.1 Physical rehabilitation therapy

    9.2.2 Therapeutic taping

    9.2.3 Aquatic Therapy

    9.3 Surgery

    9.3.1 Nerve graft

    9.3.2 Nerve transfer

    9.3.3 Muscle transfer

    10 Global Brachial Plexus Injury Market, by Indication

    10.1 Introduction

    10.2 Trauma

    10.3 Inflammation

    10.4 Contact sports

    10.5 Tumors

    10.6 Radiation treatment

    10.7 Others

    11 Global Brachial Plexus Injury Market, by Region

    11.1 Introduction

    11.2 Americas

    11.2.1 North America

    11.2.1.1 U.S.

    11.2.1.2 Canada

    11.2.2 Latin America

    11.3 Europe

    11.3.1 Western Europe

    11.3.1.1 Germany

    11.3.1.2 France

    11.3.1.3 UK

    11.3.1.4 Italy

    11.3.1.5 Spain

    11.3.1.6 Rest of Western Europe

    11.3.2 Eastern Europe

    11.4 Asia Pacific

    11.4.1 Japan

    11.4.2 China

    11.4.3 India

    11.4.4 Republic Of Korea

    11.4.5 Australia

    11.4.6 Rest of Asia Pacific

    11.5 Middle East & Africa

    11.5.1 United Arab Emirates

    11.5.2 Saudi Arabia

    11.5.3 Oman

    11.5.4 Kuwait

    11.5.5 Qatar

    11.5.6 Rest of Middle East & Africa

    12 Competitive Landscape

    12.1 Introduction

    12.2 Market Share Analysis

    12.3 Key Development & Strategies

    12.3.1 Key Developments

    13 Company Profile

    13.1 Novartis AG

    13.1.1 Overview

    13.1.2 Product/Business Segment Overview

    13.1.3 Financial Overview

    13.1.4 Key Development

    13.2 Abbvie Inc.

    13.2.1 Overview

    13.2.2 Product/Business Segment Overview

    13.2.3 Financial Overview

    13.2.4 Key Developments

    13.3 Johnson & Johnson

    13.3.1 Overview

    13.3.2 Product/Business Segment Overview

    13.3.3 Financial Overview

    13.3.4 Key Developments

    13.4 GlaxoSmithKline

    13.4.1 Overview

    13.4.2 Product/Business Segment Overview

    13.4.3 Financial Overview

    13.4.4 Key Developments

    13.5 Eli Lilly and Company

    13.5.1 Overview

    13.5.2 Product/Business Segment Overview

    13.5.3 Financials Updates

    13.5.4 Key Developments

    13.6 F. Hoffmann-La Roche AG

    13.6.1 Overview

    13.6.2 Product/Business Segment Overview

    13.6.3 Financial Updates

    13.6.4 Key Developments

    13.7 Merck Sharp & Dohme Corp

    13.7.1 Overview

    13.7.2 Product/Business Segment Overview

    13.7.3 Financial Updates

    13.7.4 Key Developments

    13.8 Pfizer

    13.8.1 Overview

    13.8.2 Product/Business Segment Overview

    13.8.3 Financial Updates

    13.8.4 Key Developments

    13.9 Others
    14 Appendix


    List of Tables
    TABLE 1 GLOBAL BRACHIAL PLEXUS INJURY MARKET, BY TYPE, 2020-2027 (USD MILLION)

    TABLE 2 AVULSION FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION, 2020-2027 (USD MILLION)

    TABLE 3 RUPTURE FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 4 NEURAPRAXIA FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 5 AXONOTEMESIS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 6 NEUROTEMESIS FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 7 NEUROMA FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 8 GLOBAL BRACHIAL PLEXUS INJURY MARKET, BY DRUGS, 2020-2027 (USD MILLION)

    TABLE 9 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 10 ANTICONVULSANTS FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 11 TRICYCLIC ANTIDEPRESSANTS FOR BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 12 GLOBAL BRACHIAL PLEXUS INJURY MARKET, BY DAIGNOSIS, 2020-2027 (USD MILLION) TABLE

    TABLE 13 GLOBAL BRACHIAL PLEXUS INJURY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 14 GLOBAL BRACHIAL PLEXUS INJURY MARKET, BY INDICATION, 2020-2027 (USD MILLION)

    TABLE 15 GLOBAL BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 16 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 17 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET, BY TYPE 2020-2027 (USD MILLION)

    TABLE 18 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET, BY DRUGS 2020-2027 (USD MILLION)

    TABLE 19 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET, BY DAIGNOSIS, 2020-2027 (USD MILLION) TABLE

    TABLE 20 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 21 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET, BY INDICATION, 2020-2027 (USD MILLION)

    TABLE 22 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET BY REGION 2020-2027 (USD MILLION

    TABLE 23 EUROPE BRACHIAL PLEXUS INJURY MARKET BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 24 EUROPE BRACHIAL PLEXUS INJURY MARKET, BY TYPE 2020-2027 (USD MILLION)

    TABLE 25 EUROPE BIOLOGICAL THERAPY MARKET, BY DRUGS 2020-2027 (USD MILLION)

    TABLE 26 EUROPE BRACHIAL PLEXUS INJURY MARKET, BY DAIGNOSIS, 2020-2027 (USD MILLION) TABLE

    TABLE 27 EUROPE BRACHIAL PLEXUS INJURY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 28 EUROPE BRACHIAL PLEXUS INJURY MARKET, BY INDICATION, 2020-2027 (USD MILLION)

    TABLE 29 EUROPE BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 30 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY COUNTRY 2020-2027 (USD MILLION)

    TABLE 31 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY TYPE 2020-2027 (USD MILLION)

    TABLE 32 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY DRUGS 2020-2027 (USD MILLION)

    TABLE 33 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY DAIGNOSIS, 2020-2027 (USD MILLION) TABLE

    TABLE 34 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 35 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY INDICATION, 2020-2027 (USD MILLION)

    TABLE 36 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 37 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)

    TABLE 38 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY TYPE 2020-2027 (USD MILLION)

    TABLE 39 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY DRUGS 2020-2027 (USD MILLION)

    TABLE 40 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY DAIGNOSIS, 2020-2027 (USD MILLION) TABLE

    TABLE 41 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

    TABLE 42 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY INDICATION, 2020-2027 (USD MILLION)

    TABLE 43 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY REGION 2020-2027 (USD MILLION)


    List of Figures
    FIGURE 1 RESEARCH PROCESS

    FIGURE 2 MARKET DYNAMICS FOR GLOBAL BRACHIAL PLEXUS INJURY MARKET

    FIGURE 3 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2020

    FIGURE 4 BRACHIAL PLEXUS INJURY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS

    FIGURE 5 GLOBAL BRACHIAL PLEXUS INJURY MARKET SHARE, BY TYPE 2020

    FIGURE 6 GLOBAL BRACHIAL PLEXUS INJURY MARKET SHARE, BY DRUGS, 2020

    FIGURE 7 GLOBAL BRACHIAL PLEXUS INJURY MARKET SHARE, BY DAIGNOSIS, 2020

    FIGURE 8 GLOBAL BRACHIAL PLEXUS INJURY MARKET SHARE, BY TREATMENT, 2020

    FIGURE 9 GLOBAL BRACHIAL PLEXUS INJURY MARKET SHARE, BY INDICATION, 2020

    FIGURE 10 GLOBAL BRACHIAL PLEXUS INJURY MARKET SHARE, BY REGION, 2020

    FIGURE 11 NORTH AMERICA BRACHIAL PLEXUS INJURY MARKET SHARE, BY COUNTRY, 2020

    FIGURE 12 EUROPE BRACHIAL PLEXUS INJURY MARKET SHARE, BY COUNTRY, 2020

    FIGURE 13 ASIA PACIFIC BRACHIAL PLEXUS INJURY MARKET SHARE, BY COUNTRY, 2020

    FIGURE 14 MIDDLE EAST & AFRICA BRACHIAL PLEXUS INJURY MARKET, BY REGION, 2020

    FIGURE 15 GLOBAL BRACHIAL PLEXUS INJURY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

    FIGURE 16 AMGEN INC.: KEY FINANCIALS

    FIGURE 17 AMGEN INC.: SEGMENTAL REVENUE

    FIGURE 18 AMGEN INC.: GEOGRAPHICAL REVENUE

    FIGURE 19 GALXOSMITHKLINE.: KEY FINANCIALS

    FIGURE 20 GALXOSMITHKLINE.: SEGMENTAL REVENUE

    FIGURE 21 GALXOSMITHKLINE: GEOGRAPHICAL REVENUE

    FIGURE 22 NOVARTIS AG: KEY FINANCIALS

    FIGURE 23 NOVARTIS AG: SEGMENTAL REVENUE

    FIGURE 24 NOVARTIS AG: GEOGRAPHICAL REVENUE

    FIGURE 25 ELI LILLY AND COMPANY.: KEY FINANCIALS

    FIGURE 26 ELI LILLY AND COMPANY.: SEGMENTAL REVENUE

    FIGURE 27 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE

    FIGURE 28 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE

    FIGURE 29 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE

    FIGURE 30 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL REVENUE

    FIGURE 31 MERCK & CO., INC: FINANCIAL REVENUE

    FIGURE 32 MERCK & CO., INC: SEGMENTAL REVENUE

    FIGURE 33 MERCK & CO., INC: GEOGRPAHICAL REVENUE

    FIGURE 34 PFIZER INC: FINANCIAL REVENUE

    FIGURE 35 PFIZER INC: SEGMENTAL REVENUE

    FIGURE 36 PFIZER INC: GEOGRPAHICAL REVENUE